COMPANY
BioVolutions is a CRO servicing clients
whose interests range from preformulation to clinical trial manufacturing.
BioVolutions' mission is to save time and minimize costs required
to obtain tox supplies and clinical trial material.
Limit your tech transfer to one single service provider
BioVolutions is your single service provider to develop
your formulation and drug delivery system, enable technology
transfer under GLP and obtain your Clinical Trial Material (CTM)
under GMP.
BioVolutions built a specific expertise and capabilities
to develop a compelling offering that optimizes your time
and costs to obtain your Clinical Trial Material.
Minimize your formulation costs
BioVolutions helps clients to decrease their fixed costs
by out-sourcing formulation services.
BioVolutions is your ideal partner to outsource your formulation
developments by reducing your costs, accelerating your product
development and complementing your expertise.
Enable technology transfer
BioVolutions provides project management to accelerate
technology transfer to the Contract Manufacturing Organization
(CMO).
BioVolutions has the experience and expertise for successful
technology transfer in the context of GMP.
Obtain your Clinical Trial Material
BioVolutions releases or rejects each batch of Clinical
Trial Material based on a cumulative review of completed manufacturing
records and other relevant information
BioVolutions is responsible for releasing or rejecting each batch
of Clinical Trial Material based on a cumulative review of completed
manufacturing records and other relevant information.
Maximize your Revenues
BioVolutions maximizes your revenues by maximizing the
therapeutic index of your molecules through formulation, analytic
and in vitro testing in a GMP Laboratory.
Give your product a competitive edge
BioVolutions protects your revenues and market share by
assessing the impact of patent expiration.
BioVolutions helps clients to protect their market share by
creating a new product via reformulation of their current drug
product. Drug Delivery technologies are the least expensive
and most reliable way to diversify a product by expanding market
penetration capabilities with a maximized Therapeutic Index.
Enable or accelerate market entry
Enabling more active substances to proceed to clinical
trials and more products to reach the market.
BioVolutions develops a formulation with the intent of maximizing
the therapeutic index by rapidly screening out problem formulations
using various analytical, dissolution testing and in-vitro
assays.
Capabilities
Maurizio Cattaneo, PhD founded BioVolutions to offer services
originating from his many years of expertise in formulation development,
drug delivery and analytical development. Dr. Cattaneo obtained
his PhD at McGill University under the direction of Dr.
Thomas W Chang, the pioneer of microencapsulation for medical applications.
Dr. Cattaneo contribution to bioanalytical development centered
on the development of new analytical assays based on amperometry
and chemiluminescence.
Select Formulation and Drug Delivery Publications
- Cattaneo, M.V. and T.M.S. Chang, The potential of a Microencapsulated
Urease-Zeolite Oral Sorbent for the Removal of Urea in Uraemia. Trans.
Am. Soc. Artif. Intern. Organs 37:80-87,
1991.
- Cattaneo MV and Demierre MF. Biodegradable Chitosan for Topical
Delivery of Retinoic Acid. Drug Del Tech 1:44-48, 2001
- Lewandrowski, Kai-Uwe; Bondre; Shrikar; Trantolo; Debra
J.; Cattaneo; Maurice V.; Gresser; Joseph D.; Wise; Donald
L. (2003) Tissue transplant coated with biocompatible biodegradable
polymer. US Patent 6,551,355
- Lewandrowski; Kai-Uwe; Bondre; Shrikar; Trantolo; Debra J.;
Cattaneo; Maurice V.; Gresser; Joseph D.; Wise; Donald L. (2005).
Osteoinduction of cortical bone allografts by coating with biopolymers
seeded with recipient periosteal bone cells. US Patent 6,899,107
- Cattaneo MV. Topical Delivery Systems Based on Polysaccharide
Microspheres. (2005) In: Delivery System Handbook for Personal
Care and Cosmetic Products. MR Rosen (Ed). William Andrew
Publ. pp.273-28.
Analytical and In Vitro Assay Publications:
- Cattaneo, M.V., J.H.T. Luong and S. Mercille (1992). Monitoring
glutamine in mammalian cell cultures using an amperometric biosensor. Biosens.
Bioelectr. 7:329-334.
- Cattaneo, M.V. and J.H.T. Luong (1993). On-line chemiluminescence
assay using FIA and fiber optics for urinary and blood glucose. Enz.
Microb. Technol. 15:424-428
- Cattaneo, M.V. and J.H.T. Luong (1994) A stable water soluble
tetramethylbenzidine:hydroxypropyl cyclodextrin inclusion complex
and its application in enzyme assays. Anal. Biochem. 223:313-320,
1994.
- Luong, J.H.T, Male K.B. and M.V. Cattaneo. (1995). Method and
System for Determining Bioactive Substances. US Patent No. 5,411,866.
Management:
Maurizio Cattaneo, Ph.D., Founder, President and CEO
Dr. Maurizio Cattaneo, Founder, President and Chief Executive
Officer of BioVolutions Inc. has 15 years experience in formulation
development and drug delivery. In 2005, Dr. Cattaneo founded
BioVolutions to serve the pharmaceutical industry in contract
formulation development and the CMC section of the IND. At BioVolutions,
Dr Maurizio Cattaneo is in charge of GLP-compliance and quality
control and oversees formulation development, analytics and in-vitro
testing. In 1997, Dr Cattaneo founded IVREA Pharmaceuticals Inc. to develop
transdermal and topical products based on reformulating generic
APIs. He invented and headed topical and transdermal drug delivery
development of IVREA’s dermatological products. Previously
Dr Cattaneo was a Director of Technology at Cambridge Scientific
Inc. in the area of injectable implants and Research Officer at
the National Research Council of Canada. Dr Cattaneo has been granted
6 U.S. patents and has numerous publications in formulation and
drug delivery including “Cattaneo MV and Demierre MF. Biodegradable
Chitosan for Topical Delivery of Retinoic Acid. Drug Del Tech 1:44-48,
2001”. Dr. Cattaneo received his Ph.D. in Chemical Engineering
at McGill University from Professor Thomas H. Chang in the area
of oral encapsulation.
Success Story:
By effectively increasing the Therapeutic Index by an
order of magnitude of Johnson & Johnson RetinA® product,
Dr Maurizio Cattaneo enabled IVREA Pharmaceuticals to implement
a full product development program.
With the intent of improving the therapeutic index of a molecule,
retinoic acid, with a known skin irritation profile and poor patient
compliance. Dr. Cattaneo, reformulated the molecule and submitted
the new formulation to J&J for evaluation. J&J confirmed
that the new formulation exhibited bioequivalence as measured using
the gold standard rhino mouse acne model while significantly reducing
irritation as measured using the standard Draize irritation model.

BioVolutions is a member of Massachusetts Biotechnology Council |